Celltrion Will Market Subcutaneous Remsima Directly After EU Nod
Executive Summary
Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.